Oral and Sublingual Epitalon: Bioavailability and Scientific Evidence

Orally administered Epitalon (Epithalon; AEDG, Ala-Glu-Asp-Gly) has been used in published rodent studies, although its absolute oral bioavailability in humans has not been established. Nor has a significant body of peer-reviewed research regarding the pharmacokinetics, absorption, or clinical efficacy of sublingually administered Epitalon been identified. [1–4]

Questions concerning oral Epitalon, Epitalon capsules, tablets, and sublingual Epitalon often rely on the assumption that since AEDG consists of only four amino acids, it must survive the digestive process and successfully enter the circulation. Published evidence does not support such an assumption.

There are actual animal studies regarding oral Epithalon, particularly conducted by Vladimir Khavinson and his colleagues. These studies show that oral administration of AEDG may be associated with measurable biological changes in rats. [1] However, they typically do not provide the pharmacokinetic data necessary to determine systemic bioavailability: blood concentrations of intact Epitalon over time, maximum concentration, area under the concentration–time curve, the percentage of the oral dose reaching the circulation, comparison with the reference injection route, or the differentiation between the intact peptide and its degradation products.

Evidence regarding the sublingual route is even more limited. While a given route of administration may be commercially available or theoretically appealing, this does not mean that it has been confirmed in peer-reviewed studies specific to Epitalon.

The key distinction throughout the article is therefore as follows:

Biological activity after oral administration is not the same as the demonstrated bioavailability of intact Epitalon after oral administration.

Is Oral Epitalon Bioavailable?

Oral Epitalon it produced measurable effects in rodent studies, demonstrating that oral administration is biologically significant under experimental conditions. However, no robust pharmacokinetic study in humans has been conducted to determine what amount of intact AEDG reaches the systemic circulation after ingestion. Therefore, based on peer-reviewed evidence, a specific percentage of oral bioavailability cannot currently be provided. [1–4]

The strongest direct evidence regarding oral Epitalon comes from older animal studies.

Khavinson and co-workers administered Epithalon orally for one month to older Wistar rats and then examined enzyme activity in various layers of the small intestine. The researchers noted an increase in the activity of maltase and alkaline phosphatase in the epithelium following oral exposure to Epithalon. [1]

This study confirms a significant, but limited, conclusion:

Epitalon was administered orally and was associated with measurable biological effects in the intestines of rats.

However, it was not established whether these effects required the intact peptide to enter the systemic circulation. When taken orally, the substance may act locally on the tissues of the gastrointestinal tract, undergo partial degradation into active fragments, influence signalling in the gut wall, or be absorbed to some extent. The study did not distinguish between these possibilities by measuring the pharmacokinetics of AEDG in plasma.

The comprehensive 2025 review of Epitalon also accounts for oral administration in the historical evidence base, but does not provide a confirmed percentage of oral absorption or systemic bioavailability in humans. [2]

This is particularly important because bioavailability has a specific pharmacokinetic meaning. Absolute oral bioavailability usually requires a comparison of systemic exposure following oral administration with exposure following intravenous administration or another suitably characterised reference route.

None of the analysed studies regarding Epitalon provide such a pharmacokinetic comparison in humans.

Therefore, statements such as:

• „Epitalon is fully bioavailable after oral administration,
• „Oral Epitalon is absorbed at a rate of 80%”
• or
• „the tetrapeptide is small enough to survive digestion in intact form”

require direct pharmacokinetic data on Epitalon. Such evidence has not been established in the analysed literature.

What Happens to Peptides in the Digestive Tract?

Orally administered peptides are exposed to gastric conditions, pancreatic and intestinal proteases, brush-border peptidases, mucus, and the poorly permeable intestinal epithelium. These barriers often limit peptide stability and systemic absorption, although the exact susceptibility varies considerably depending on sequence, structure, formulation, molecular size, and transport pathway. [3–6]

Oral delivery of peptides is difficult for two main reasons: enzymatic degradation and limited membrane permeability.

Proteolysis and peptide degradation

Proteins and peptides entering the digestive tract are exposed to digestive enzymes adapted to break down peptide bonds.

Depending on the molecule and location, these can be gastric proteases, pancreatic enzymes, and peptidases located in the brush border of the intestine.

A 2020 peer-reviewed review on peptide and protein absorption indicates that peptide drugs are often characterised by poor stability in the gastrointestinal tract and low membrane permeability, which limits their oral absorption. [3]

A broader review on oral peptide delivery also points to enzymatic degradation and low intestinal permeability as the two main barriers to clinically effective oral peptide formulations. [5]

However, these are general principles regarding the delivery of peptides, rather than direct measurements of Epitalon.

Epitalon is a linear tetrapeptide, meaning that it is significantly smaller than insulin, growth hormone, or many therapeutic peptides. The smaller size could theoretically affect absorption or resistance to certain degradation mechanisms, but size alone is not enough to determine bioavailability.

The polarity of the peptide, hydrogen bonds, accessibility of the molecule ends, charge, sequence, conformation and recognition by transporters may also be of importance.

Intestinal permeability

Even if the peptide remains intact in the intestinal lumen, it still has to cross the epithelial barrier to enter the systemic circulation.

Hydrophilic peptide molecules typically do not easily penetrate lipid-rich cell membranes. Studies comparing peptide molecular size and permeability have shown that an increase in molecular weight often correlates with poorer intestinal permeability, although the behaviour of individual peptides can vary significantly. [6]

There are exceptions.

Some small peptides can interact with intestinal peptide transport systems, whereas specific cyclic or chemically modified peptides can achieve significant exposure after oral administration. Reviews concerning orally absorbed cyclic peptides show that structure, and not just the number of amino acids, has a major influence on systemic absorption. [7]

Epitalon is not a cyclic peptide, and available literature does not show that it effectively utilises a specific intestinal transporter to a degree that allows for predictable systemic exposure in humans.

General knowledge about peptide absorption therefore justifies a thorough study of oral Epitalon, but it cannot replace direct pharmacokinetic measurements.

Has Sublingual Epitalon Been Studied?

No significant body of peer-reviewed research specifically dedicated to sublingual Epitalon has been identified. Current scientific evidence does not determine the percentage of sublingual absorption, pharmacokinetics, optimal formulation, comparative bioavailability, efficacy or safety specific to this route of administration. Therefore, claims of superior sublingual delivery require direct experimental evidence.

The sublingual route involves placing a substance under the tongue, where it can come into contact with the highly vascular oral mucosa.

Theoretically, administration via the mucous membrane can make it possible to avoid some of the degradation in the gastrointestinal tract and the first-pass effect, which affect swallowed substances. This is one of the reasons why the sublingual route is of interest in the case of molecules with poor oral absorption.

However, the possibility of such delivery depends to a large extent on the properties of the specific molecule.

The peptide must remain stable in saliva, penetrate the mucus and epithelial tissue, avoid rapid degradation, and enter the systemic circulation in a sufficient amount.

General studies analysed strategies to improve the absorption of peptides across mucosal membranes, including permeation enhancers, protease inhibitors, chemical modifications and specialised formulations. [3]

However, this does not prove that unmodified AEDG is effectively absorbed sublingually.

In the peer-reviewed literature analysed for the purposes of this article, no Epitalon-specific controlled trial was identified that measured:

• plasma concentrations following sublingual administration,
• absolute or relative bioavailability,
• time to maximum concentration,
• dose proportionality,
• mucosal permeability,
• an intact AEDG compared to its breakdown products,
• or a direct comparison with oral or injected Epitalon.

Therefore, the commercial availability of the sublingual product should not be equated with the clinical confirmation of this route of administration.

The claim that „sublingual Epitalon bypasses digestion and therefore has high bioavailability” contains a theoretically plausible first element, but an unconfirmed conclusion specific to Epitalon.

How Does Oral Epitalon Compare to Injection?

Injection bypasses the digestive process in the gastrointestinal tract and was widely used in animal studies of Epitalon, whereas oral administration exposes AEDG to gastrointestinal barriers. However, no robust direct human pharmacokinetic study comparing the bioavailability of oral and injectable Epitalon has been conducted, so the magnitude of the potential difference in exposure remains unknown. [1,2]

The conceptual difference between these roads is simple.

During subcutaneous or intramuscular injection, Epitalon does not pass through the lumen of the digestive tract first. The peptide still needs to be absorbed from the site of administration and can undergo enzymatic degradation at other sites, but it bypasses intestinal digestion.

When administered orally, the compound is exposed to the conditions prevailing in the stomach and intestines before systemic absorption can take place.

For this reason, many therapeutic peptides have historically required parenteral administration, and the development of oral peptide drugs often depends on advanced formulation strategies. [3,5]

Epitalon-specific research reflects this difference.

In older experiments concerning lifespan, carcinogenesis and the endocrine system, subcutaneous injections were frequently used, whereas oral studies were much fewer and often focused on gastrointestinal physiology rather than systemic pharmacokinetics. [1,2]

However, this scheme should not be turned into an evidence-free numerical comparison.

There is no evidence in the analysed literature to justify statements such as:

• „Epitalon administered by injection has a tenfold higher bioavailability,
• „Oral Epitalon is just as effective as the injection in X%”
• or
• „a higher oral dose provides equivalent systemic exposure.

Answering these questions requires actual pharmacokinetic data.

The current evidence can be compared as follows:

The injection therefore has a longer history of preclinical research, but this should not be presented as evidence of greater clinical efficacy in humans.

A detailed comparison of the administration routes can be found in the article Epitalon Injection and Administration Routes in Research.

Does Epitalon in Capsules or Tablets Have Clinical Evidence?

There is no strong clinical evidence in humans confirming that Epitalon capsules or tablets provide predictable systemic exposure or clinically relevant effects related to ageing, sleep, telomeres or longevity. Published studies concerning oral administration are mainly derived from rodent models, and the mere availability of a specific product form does not prove absorption, efficacy or pharmaceutical equivalence.

A capsule or tablet is a product form, not proof of bioavailability.

For the oral formulation of Epitalon to have a well-characterised evidence base, researchers should demonstrate that:

• contains chemically verified AEDG,
• remains stable during storage,
• releases the peptide in a predictable manner,
• protects it appropriately during its passage through the digestive tract when necessary,
• leads to a detectable plasma concentration of intact AEDG,
• it has reproducible pharmacokinetics,
• and produces significant effects in controlled human trials.

Such evidence has not been established for general Epitalon capsules or tablets.

Older studies on rats show that Epithalon can be administered orally, but generally do not describe modern capsule or tablet formulations with confirmed pharmacokinetics. [1]

This distinction is particularly important in the case of marketing claims.

The sale of a product in capsule form does not prove that its formulation replicates the exposure achieved in animal experiments.

Similarly, observing a biological response in the intestines of rats does not prove that ingestion of a commercial tablet leads to therapeutic concentrations of intact AEDG in human tissues.

The broader literature on oral peptides shows why formulation can make a huge difference. For many peptide drugs, strategies such as protease inhibition, permeability enhancement, structural modification and specialised delivery systems may be needed to overcome gastrointestinal barriers. [3,5]

Whether a specific Epitalon capsule effectively overcomes these barriers must be demonstrated, not assumed.

What Routes of Administration Were Used in Khavinson's Studies?

In Khavinson's research on Epitalon, various administration routes were used rather than a single standard protocol. These included subcutaneous injections in numerous studies on ageing and cancer, and oral Epithalon in rodent gastrointestinal studies. The choice of route depended on the research question, and the historical research programme did not establish a single universal oral or sublingual regimen for humans. [1,2]

The view that there was a single standard „Khavinson method of Epitalon administration” is not supported by publications.

Many classic gerontological experiments used injections.

For example, in studies on mouse longevity and the spontaneous development of tumours, Epitalon was often administered subcutaneously according to intermittent schedules. In other studies on rats, parenteral administration was also used.

However, Khavinson and colleagues also investigated oral Epithalon.

In a 2002 study, Epithalon was administered orally to older Wistar rats for one month, evaluating the activity of small intestine enzymes. [1]

Related studies analysed the effect of oral Epithalon on glucose and glycine absorption and other gastrointestinal functions in older rats.

It can therefore be correctly stated that Khavinson's research programme involved oral administration.

However, it cannot be concluded on this basis that:

• oral Epitalon had confirmed high bioavailability in humans,
• oral administration was shown to be equivalent to injection,
• the specific capsule formulation has been clinically proven,
• or sublingual administration was part of the established protocol for humans.

Original experiments should be interpreted in accordance with the route, species, endpoint, and study design actually used.

Which Bioavailability Claims Require Direct Evidence?

Any claim attributing a specific oral or sublingual absorption percentage to Epitalon, indicating equivalence to injection, confirming the delivery of the intact peptide to the blood or brain, or recognising one route as clinically superior requires direct pharmacokinetic evidence. Biological effects in animals, the size of the peptide or theoretical transport mechanisms cannot replace measured exposure in humans.

„Oral Epitalon has high bioavailability”

Such a claim requires the measurement of intact Epitalon in the systemic circulation following oral administration and, ideally, the calculation of absolute bioavailability relative to a reference intravenous administration.

Published gut studies on rats do not provide such information. [1]

„Epitalon survives digestion because it consists of only four amino acids”

Small size may affect stability and transport, but it does not prove resistance to proteolysis in the gastrointestinal tract.

General literature regarding peptide delivery shows that even relatively small peptides can encounter both enzymatic and permeability barriers. [3–6]

Direct studies of its digestion would be required to determine the survival rate of intact Epitalon.

„Sublingual Epitalon bypasses digestion and is therefore well absorbed”

Sublingual administration may allow a significant part of the gastrointestinal tract to be bypassed, provided that AEDG indeed effectively penetrates the oral mucosa.

This second element remains undefined for Epitalon.

Simply bypassing the digestive tract does not automatically mean effective penetration through the mucous membrane.

„Oral Epitalon crosses the blood–brain barrier”

Such a claim would require an even higher level of proof.

First, it would be necessary to demonstrate the systemic absorption of intact Epitalon following oral administration, and then confirm exposure in the central nervous system or its transport.

The analysed literature regarding oral Epitalon does not provide such data.

„Capsules are equivalent to injections”

This would require a direct pharmacokinetic comparison demonstrating comparable exposure, preferably together with comparable pharmacodynamic or clinical outcomes.

No such confirmed comparison in humans has been identified.

„A larger amount of oral Epitalon compensates for poor absorption”

Such a claim is also not scientifically justified without knowledge of the dose-response relationship and adequate safety data.

An increase in the nominal amount does not necessarily lead to a proportional increase in systemic exposure, and the unabsorbed material may still interact with the gastrointestinal tract.

What Do Studies on Oral Epitalon Actually Confirm?

The difference between what has been demonstrated and what remains unknown can be summarised as follows:

The most justified conclusion is therefore narrower than many commercial claims:

Oral administration is a genuine part of the literature concerning Epitalon in animal studies, yet the pharmacokinetics of intact AEDG following oral or sublingual administration in humans remains insufficiently characterised.

Frequently Asked Questions about Oral and Sublingual Epitalon

Is oral Epitalon effective?

Oral Epitalon produced measurable biological effects in rodent studies, particularly concerning intestinal enzymes and nutrient transport physiology. However, controlled evidence in humans confirming clinical efficacy following oral administration has not been established. Furthermore, biological effects in rats do not prove that intact AEDG reaches the human systemic circulation in concentrations of therapeutic significance. [1]

Is oral Epitalon bioavailable?

Some degree of local or systemic biological exposure may occur, as biological effects have been observed in animal studies following oral administration. However, the absolute bioavailability of intact Epitalon following oral administration has not been determined in humans. Therefore, without direct pharmacokinetic data, a reliable percentage should not be given.

Does Epitalon survive the action of stomach acid and digestive enzymes?

This has not been properly quantified in direct human studies of Epitalon. General peptide pharmacology shows that peptide drugs can be degraded by gastrointestinal enzymes and exhibit poor intestinal permeability, but the exact stability profile of AEDG in the human gastrointestinal tract requires Epitalon-specific studies. [3–5]

Has sublingual Epitalon been scientifically researched?

No significant base of peer-reviewed research specific to sublingual Epitalon has been identified. Human sublingual pharmacokinetics, absolute bioavailability, optimal formulation, dose-response relationship, and efficacy compared to oral or injectable Epitalon remain unestablished.

Does sublingual Epitalon absorb better than oral?

This has not been demonstrated in a direct study of Epitalon. Sublingual administration could theoretically limit proteolysis in the gastrointestinal tract if AEDG successfully penetrates the oral mucosa. However, there is a lack of solid direct pharmacokinetic data determining whether sublingual Epitalon actually provides greater systemic exposure.

Do Epitalon capsules work?

There is no strong clinical evidence to indicate that generally available Epitalon capsules provide reliable systemic exposure to AEDG or confirmed human benefits related to ageing, telomeres, sleep or longevity. Published oral animal studies should not be regarded as confirmation of commercial capsule formulations.

Have Epitalon tablets been clinically confirmed?

No. The mere availability of the product in tablet form does not confirm its pharmacokinetics or efficacy. A clinically validated oral tablet would require stability data for the specific formulation, release, absorption, pharmacokinetics, safety and clinical outcomes, which have not been established for Epitalon.

Is injected Epitalon more bioavailable than oral?

Injection bypasses gastrointestinal digestion, and therefore there is a pharmacological rationale to expect a different level of exposure. However, the scale of this difference has not been adequately determined in human studies of Epitalon. Providing a specific coefficient or percentage difference would therefore be unjustified.

Can oral Epitalon reach the brain?

Direct evidence in humans has not shown that intact Epitalon administered orally reaches the brain. Credible confirmation of such a claim would first require demonstrating systemic absorption following oral administration, followed by measurement or convincing evidence of central nervous system exposure.

Limitations of Evidence Regarding Oral and Sublingual Administration

The biggest limitation is the lack of direct pharmacokinetic measurements.

The biological response following oral administration does not explain whether intact Epitalon entered the systemic circulation, what amount of it was absorbed, how quickly it appeared in the blood, or how long it remained detectable.

Secondly, most of the direct evidence concerning oral administration comes from studies on rats, not humans.

Gastrointestinal physiology, peptide metabolism, transporter expression, body size and intestinal transit in rodents differ from those in humans.

Thirdly, some oral studies have focused specifically on the gastrointestinal tract. The change in intestinal maltase or alkaline phosphatase activity could theoretically result from a local effect, and therefore cannot be regarded as evidence of high systemic exposure. [1]

Fourthly, general principles of peptide pharmacology should not be unduly transposed to Epitalon. It is true that peptide drugs often encounter barriers related to proteolysis and permeability. [3–6] However, it would not be correct to derive the exact absorption value of Epitalon from studies on other peptides.

Fifthly, evidence concerning sublingual administration is particularly limited. Commercial availability, user reports, or the theoretical bypassing of degradation in the gastrointestinal tract do not prove absorption through the mucous membrane.

Finally, formulation matters. A simple aqueous solution of AEDG, a capsule, a tablet, an enteric-coated formulation, and a sublingual product can lead to very different exposure profiles. Studies of one cannot automatically validate the others.

Future research on the oral delivery of Epitalon should ideally measure intact AEDG using validated LC-MS/MS methods following strictly defined oral and sublingual administration, generate concentration-time curves, determine absolute bioavailability, identify metabolites, compare routes of administration, and correlate systemic exposure with pharmacodynamic outcomes.

Until such data are available, precise claims regarding oral and sublingual bioavailability should be clearly designated as unconfirmed.

Disclaimer

This article is for educational, scientific and informational purposes only and does not constitute medical advice, dosing instructions, guidance on choosing the route of administration or a recommendation for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental peptide, and oral and sublingual administration has not been confirmed in robust contemporary human studies as an approved treatment for anti-ageing, telomere modification, sleep, longevity or other proposed uses. The evidence discussed regarding oral administration is primarily preclinical in nature, whereas the pharmacokinetics and clinical efficacy of sublingual administration in humans remain insufficiently characterised. Experimental routes of administration or animal dosing regimens should not be translated into self-administration protocols.